Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
Astrazeneca Plc $AZN Shares Bought by Apollon Wealth Management LLC
03:30am, Sunday, 12'th Apr 2026
Apollon Wealth Management LLC grew its position in Astrazeneca Plc (NYSE: AZN) by 318.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside
10:31am, Friday, 10'th Apr 2026
UBS and Citi both maintain 'buy' ratings on the Anglo-Swedish drugmaker ahead of its first-quarter results, with a rich pipeline of clinical catalysts...
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside
09:54am, Friday, 10'th Apr 2026
UBS and Citi both maintain 'buy' ratings on the Anglo-Swedish drugmaker ahead of its first-quarter results, with a rich pipeline of clinical catalysts adding to the investment case. AstraZeneca PLC (L
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?
10:21am, Thursday, 09'th Apr 2026
Though both dominate oncology, a stronger growth outlook and clearer targets may give AstraZeneca an edge over Merck.
Center For Asset Management LLC Purchases Shares of 3,430 Astrazeneca Plc $AZN
04:44am, Wednesday, 08'th Apr 2026
Center For Asset Management LLC purchased a new stake in shares of Astrazeneca Plc (NYSE: AZN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The instituti
AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug
07:50am, Tuesday, 07'th Apr 2026
A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZeneca's most important growth drivers. Liver cancer is one...
AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug
07:15am, Tuesday, 07'th Apr 2026
A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZeneca's most important growth drivers. Liver cancer is one of the most difficult cancers to treat, and
Perpetual Ltd Has $515,000 Stock Holdings in Astrazeneca Plc $AZN
06:05am, Monday, 06'th Apr 2026
Perpetual Ltd decreased its position in shares of Astrazeneca Plc (NYSE: AZN) by 60.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exc
Aspiriant LLC Takes $236,000 Position in Astrazeneca Plc $AZN
03:26am, Monday, 06'th Apr 2026
Aspiriant LLC purchased a new position in Astrazeneca Plc (NYSE: AZN) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The insti
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns
08:45am, Sunday, 05'th Apr 2026
AstraZeneca remains a long-term buy, driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly stretched. AZN's 2025 results showed 8% revenue and 11%
Astrazeneca (AZN) Rises Higher Than Market: Key Facts
07:15pm, Thursday, 02'nd Apr 2026
Astrazeneca (AZN) concluded the recent trading session at $203.49, signifying a +1.37% move from its prior day's close.
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
05:34pm, Thursday, 02'nd Apr 2026
Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.
Global pharma companies that have publicly announced Trump drug pricing agreements
02:59pm, Thursday, 02'nd Apr 2026
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye
Pre-Market Stock Futures: Risk-on appeared back, at least for the last two days, as the stock market put together another rally on Wednesday, with hopes for an end to the war in Iran and some solid ec
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial
06:47am, Thursday, 02'nd Apr 2026
AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a common liver cancer lived before their disease wors
